Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 138 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
138 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with locally advanced/metastatic urothelial carcinoma harboring activating FGFR2/3 alterations after progression on platinum and a PD‑1/L1 inhibitor (including cisplatin-ineligible) receive erdafitinib (oral pan-FGFR1–4 TKI) plus enfortumab vedotin (Nectin‑4–targeted MMAE ADC). Requires measurable disease and adequate organ function; excludes prior FGFR inhibitors or enfortumab/MMAE ADCs and significant ocular/cardiovascular issues.
ClinicalTrials.gov ID: NCT04963153
HealthScout AI summary: Adults with relapsed/refractory metastatic RCC (clear cell or papillary), EBV-associated NPC, or advanced NHL (including DLBCL, FL, MCL) receive GEN1160 (PRO1160), a CD70-directed antibody–drug conjugate delivering an exatecan topoisomerase-1 inhibitor payload, given IV Day 1 of 21-day cycles; expansion focuses on DLBCL NOS after ≥2 prior regimens including CD20 chemoimmunotherapy. Excludes prior CD70 therapy/topo-1 ADCs, recent transplants/intensive therapy, active CNS disease (expansion), and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT05721222
HealthScout AI summary: Adults with locally advanced or metastatic clear cell RCC (any VHL status) receive oral HC-7366—an activator of the GCN2 integrated stress response pathway—either alone or combined with belzutifan (HIF-2α inhibitor), with combination dose escalation/expansion to define MTD/RP2D. Suitable for patients needing a belzutifan-based regimen or eligible for first- or later-line investigational therapy in ccRCC.
ClinicalTrials.gov ID: NCT06234605
HealthScout AI summary: Adults with advanced, HLA‑G–positive solid tumors (ECOG 0–1) after standard therapies receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, then a single infusion of IVS‑3001, an autologous third‑generation CAR‑T targeting HLA‑G (an immune checkpoint ligand for ILT2/ILT4). Phase 2a includes cohorts for clear cell RCC post‑CPI/TKI, epithelial ovarian cancer post‑platinum (± prior PARP if BRCA1/2‑mutant), and other HLA‑G+ tumors without standard options.
ClinicalTrials.gov ID: NCT05672459
HealthScout AI summary: Adults with AML/MDS or other cancers lacking standard options are enrolled into cohorts with severe renal impairment (CLcr <30 mL/min, not on dialysis) or normal renal function to receive the approved fixed-dose oral decitabine/cedazuridine (35/100 mg) regimen. Decitabine is a DNA methyltransferase inhibitor (hypomethylating agent) and cedazuridine is a cytidine deaminase inhibitor that boosts decitabine bioavailability; the study compares pharmacokinetics and safety between renal function groups.
ClinicalTrials.gov ID: NCT04953897
HealthScout AI summary: Adults with metastatic/unresectable melanoma (PD‑1–refractory or PD‑1–naïve) or metastatic clear‑cell RCC refractory to PD‑1/PD‑L1–based therapy receive pembrolizumab (PD‑1 blockade) combined with high‑dose aldesleukin/IL‑2 (T‑cell activation) given inpatient. Single‑arm design aims to improve objective response; excludes significant autoimmune disease, prior severe irAEs, active infection, or major cardiopulmonary compromise.
ClinicalTrials.gov ID: NCT05155033
HealthScout AI summary: Adults with advanced/metastatic solid tumors after standard therapy receive REGN10597, an intravenously delivered anti–PD-1–IL2RA–IL2 fusion protein designed to target IL-2 signaling to PD-1–positive activated T cells while limiting systemic IL-2 effects; expansion cohorts enroll melanoma and clear-cell RCC. Key exclusions include prior IL-2/IL-15/IL-7 therapy, recent checkpoint inhibitors or systemic therapy, active immune-related AEs, significant autoimmune disease, or need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06413680
HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
HealthScout AI summary: Adults with metastatic or unresectable clear cell RCC that is CD70-positive (≥10% by IHC) after progression on at least one ICI and one TKI receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of allogeneic umbilical cord blood–derived NK cells engineered with a CD70-directed CAR and IL-15, with CRISPR knockout of TGF-β receptor type II to resist TGF-β–mediated immunosuppression. Key exclusions include active infections, autoimmune disease requiring treatment, uncontrolled CNS disease, and significant organ comorbidities.
ClinicalTrials.gov ID: NCT07072234
HealthScout AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601